Esketamine Nasal Spray for Rapid Reduction of Depressive Symptoms in Patients With Major Depressive Disorder Who Have Active Suicide Ideation With Intent: Results of a Phase 3, Double-Blind, Randomized Study (ASPIRE II)

BACKGROUND: Patients with major depressive disorder (MDD) having active suicidal ideation with intent require immediate treatment. METHODS: This double-blind study (ASPIRE II) randomized adults (aged 18–64 years) with MDD having active suicidal ideation with intent to esketamine 84 mg or placebo nas...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Int J Neuropsychopharmacol
Main Authors: Ionescu, Dawn F, Fu, Dong-Jing, Qiu, Xin, Lane, Rosanne, Lim, Pilar, Kasper, Siegfried, Hough, David, Drevets, Wayne C, Manji, Husseini, Canuso, Carla M
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2020
Assuntos:
Regular Research Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7816667/
https://ncbi.nlm.nih.gov/pubmed/32861217
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ijnp/pyaa068
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados